F-1/A: Meihua International Medical Technologies Files Amendment No. 2 to Form F-1 Registration Statement

Meihua International Medical Technologies Co., Ltd. files an amendment to its Form F-1 registration statement for the resale of ordinary shares issuable upon exercise of warrants.

Summary

• Meihua International Medical Technologies Co., Ltd., a Cayman Islands exempted company, has filed Amendment No.
• 2 to its Form F-1 registration statement with the U.S.
• Securities and Exchange Commission.
• The filing pertains to the resale of up to 1,205,255 ordinary shares, par value $0.0005 per share, of the Company exercisable at $2.9869 per share, issuable upon exercise of warrants by the Selling Shareholders.
• The company will not receive any proceeds from the sale of these ordinary shares by the Selling Shareholders.
• The Warrants and the Warrant Shares were sold in a private placement pursuant to an exemption from the registration requirements of the Securities Act of 1933.
• The company's ordinary shares are listed on the Nasdaq Capital Market under the symbol MHUA, and the last reported sale price on February 22, 2024, was $0.719.
• Investing in the company's securities involves a high degree of risk, as detailed in the prospectus and the company's most recent annual report on Form 20-F.
• Meihua is a holding company with operations conducted by its subsidiaries located in mainland China.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced public company reporting requirements.
• The company is monitoring regulatory developments in China regarding necessary approvals for overseas listings and has not received any objections to this offering from the CSRC or other PRC governmental authorities as of the date of the prospectus supplement.
• The company may be subject to orders to rectify, warnings, and fines if it fails to comply with the requirements under the Trial Measures for any future overseas securities offering or listing, or if the CSRC disagrees with our view on the applicability of the New Overseas Listing Rules to this offering by the Selling Shareholder.
• The company's Ordinary Shares may be delisted from Nasdaq or prohibited from being traded over the counter under the Holding Foreign Companies Accountable Act (HFCA Act) and related regulations if the PCAOB is unable to inspect our auditor for two consecutive years beginning in 2022.

Sentiment

Score: 5

Explanation: The document is primarily a legal filing, so the sentiment is neutral. There are some positive aspects, such as the company monitoring regulatory developments, but also negative aspects, such as the risks associated with investing in the company's securities.

Positives

• The company is monitoring regulatory developments in China regarding necessary approvals for overseas listings and has not received any objections to this offering from the CSRC or other PRC governmental authorities as of the date of the prospectus supplement.

Negatives

• Investing in the company's securities involves a high degree of risk, as detailed in the prospectus and the company's most recent annual report on Form 20-F.
• The company may be subject to orders to rectify, warnings, and fines if it fails to comply with the requirements under the Trial Measures for any future overseas securities offering or listing, or if the CSRC disagrees with our view on the applicability of the New Overseas Listing Rules to this offering by the Selling Shareholder.
• The company's Ordinary Shares may be delisted from Nasdaq or prohibited from being traded over the counter under the Holding Foreign Companies Accountable Act (HFCA Act) and related regulations if the PCAOB is unable to inspect our auditor for two consecutive years beginning in 2022.

Risks

• Investing in the company's securities involves a high degree of risk, as detailed in the prospectus and the company's most recent annual report on Form 20-F.
• The company may be subject to orders to rectify, warnings, and fines if it fails to comply with the requirements under the Trial Measures for any future overseas securities offering or listing, or if the CSRC disagrees with our view on the applicability of the New Overseas Listing Rules to this offering by the Selling Shareholder.
• The company's Ordinary Shares may be delisted from Nasdaq or prohibited from being traded over the counter under the Holding Foreign Companies Accountable Act (HFCA Act) and related regulations if the PCAOB is unable to inspect our auditor for two consecutive years beginning in 2022.

Future Outlook

The company intends to use earnings for research and development, to develop new products, and to expand its production capacity and does not expect to pay any cash dividends for the near term.

Industry Context

The medical device industry is intensely competitive and includes thousands of companies both domestically and internationally. As more medical device companies seek to outsource more of the design, prototyping and manufacturing of their products, we will face increasing competitive pressures to grow our business in order to maintain our competitive position and we may encounter competition from, and lose customers to, other companies with design, technological and manufacturing capabilities similar to ours.

Comparison to Industry Standards

• The document mentions several competitors including Shandong Weigao Group Medical Polymer Co., Limited, Jiangxi Hongda Medical Equipment Group Ltd., Henan Tuoren Medical Device Co., Ltd., Allmed Medical Products Co., Ltd., Jiangxi Sanxin Medtec Co., Ltd., and Jiangxi 3L Products Group Co., Ltd.
• These companies are involved in the research, development, manufacturing, and sales of medical devices, particularly disposable medical devices.
• The document notes that Meihua International competes with these companies but also collaborates with them in certain areas, such as distribution and supply of materials.
• The document also mentions that Meihua International's one-stop service system is a key differentiator, allowing it to supply a wide range of medical consumables to its customers.
• The document states that Meihua International's revenues accounted for approximately 10% of the total revenues generated from all medical device manufactures in Touqiao Town, and that its output value accounted for about 26.5% of the total output value of the top 20 companies in Touqiao Town in 2020.

Stakeholder Impact

• The document outlines potential risks for investors, including the possibility of delisting and regulatory changes.
• The document also mentions the company's commitment to quality and safety, which is important for customers and patients.

Next Steps

• The Selling Shareholders may sell the Warrant Shares included in this prospectus in a number of different ways and at varying prices.
• We may amend or supplement this prospectus supplement from time to time by filing amendments or supplements as required.

Key Dates

Keywords

ordinary shares, warrants, resale, registration statement, Meihua International, medical technologies, Form F-1, securities, China